Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus

A Global Case–Control Study in 13 Countries

Frank M. Sacks, MD; Michel P. Hermans, MD; Paola Fioretto, MD; Paul Valensi, MD; Timothy Davis, MD; Edward Horton, MD; Christoph Wanner, MD; Khalid Al-Rubeaan, MD; Ronnie Aronson, MD; Isabella Barzon, MD; Louise Bishop, BS, RD; Enzo Bonora, MD; Pongamorn Bunnag, MD; Lee-Ming Chuang, MD; Chaicharn Deerochanawong, MD; Ronald Goldenberg, MD; Benjamin Harshfield, BA; Cristina Hernández, MD; Susan Herzlinger-Botein, MD; Hiroshi Itoh, MD; Weiping Jia, MD; Yi-Der Jiang, MD; Takashi Kadowaki, MD; Nancy Laranjo, BA; Lawrence Leiter, MD; Takashi Miwa, MD; Masato Odawara, MD; Ken Ohashi, MD; Atsushi Ohno, MD; Changuy Pan, MD; Jiemin Pan, MD; Juan Pedro-Botet, MD; Zeljko Reiner, MD; Carlo Maria Rotella, MD; Rafael Simo, MD; Masami Tanaka, MD; Eugenia Tedeschi-Reiner, MD; David Twum-Barima, MD; Giacomo Zoppini, MD; Vincent J. Carey, PhD

Background—Microvascular renal and retinal diseases are common major complications of type 2 diabetes mellitus. The relation between plasma lipids and microvascular disease is not well established.

Methods and Results—The case subjects were 2535 patients with type 2 diabetes mellitus with an average duration of 14 years, 1891 of whom had kidney disease and 1218 with retinopathy. The case subjects were matched for diabetes mellitus duration, age, sex, and low-density lipoprotein cholesterol to 3683 control subjects with type 2 diabetes mellitus who did not have kidney disease or retinopathy. The study was conducted in 24 sites in 13 countries. The primary analysis included kidney disease and retinopathy cases. Matched analysis was performed by use of site-specific conditional logistic regression in multivariable models that adjusted for hemoglobin A1c, hypertension, and statin treatment. Mean low-density lipoprotein cholesterol concentration was 2.3 mmol/L. The microvascular disease odds ratio increased by a factor of 1.16 (95% confidence interval, 1.11–1.22) for every 0.5 mmol/L (=1 quintile) increase in triglycerides or decreased by a factor of 0.92 (0.88–0.96) for every 0.2 mmol/L (=1 quintile) increase in high-density lipoprotein cholesterol. For kidney disease, the odds ratio increased by 1.23 (1.16–1.31) with triglycerides and decreased by 0.86
Diabetes mellitus is a major cause of microvascular disease, which includes kidney disease and retinopathy and their ultimate consequences, end-stage renal disease and blindness. Hyperglycemia and hypertension are major risk factors for the development of microvascular disease. Intensive control of blood glucose and blood pressure to, or even beyond, currently recommended targets may provide some additional benefits in the prevention of diabetic microvascular disease but is often impossible to achieve because of the associated risks of hypoglycemia or hypotension. Therefore, it is necessary to identify other targets and treatments to make progress in slowing the development of diabetic kidney disease and retinopathy.

Clinical Perspective on p 1008

Most epidemiological studies have found an association between serum triglycerides and diabetic kidney disease, although less consistently for serum high-density lipoprotein cholesterol (HDL-C). Results diverged among studies on diabetic retinopathy, especially in multivariable analysis. In randomized, controlled trials, treatment of patients with type 2 diabetes mellitus with fenofibrate, a peroxisome proliferator–activated receptor-α agonist, reduced the rate of decline in renal function, reduced albuminuria, and reduced the requirement for laser treatment of retinopathy. However, it is not clear whether these beneficial effects were caused by improvements in triglycerides or HDL-C or by other biological effects of peroxisome proliferator–activated receptor-α activation.

The objective of the present international study was to determine whether low HDL-C or elevated triglycerides levels are associated with diabetic kidney disease and retinopathy independent of established determinants of microvascular disease in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≤3.4 mmol/L (130 mg/dL).

Methods

The study used a case–control design in 24 sites in 13 countries. Sites were either hospitals or diabetes clinics. The study was approved by the institutional review boards of the coordinating center and each clinical site.

Population

Case and control subjects were individuals with type 2 diabetes mellitus documented in the medical record, ≥40 years of age, with LDL-C ≤3.4 mmol/L. Data were compiled from clinical charts. All consecutive charts of patients with type 2 diabetes mellitus who met the selection criteria were processed, and the required parameters were recorded. The methodology was piloted for feasibility assessment at the site in Brussels, Belgium, and included case subjects ascertained from 1990 to 2009 (median visit date May 2006). The chart review period was in 2008 to 2010 for all other sites.

Case Subjects

Case subjects were patients with visits for ≥1 recorded ocular or renal microvascular complication (kidney disease or retinopathy, the latter also including diabetic macular edema). Patients with nondiabetic kidney disease were excluded unless they presented with a known diabetic microvascular complication. Nondiabetic kidney disease was determined by the site’s principal investigator from the medical records. The index visit for a case was a complication-related visit to which a lipid panel measured within 6 months could be associated.

Control Subjects

Control subjects were patients with type 2 diabetes mellitus with documented evidence of not having microvascular complications of the kidney and eye as defined below.

Case Definitions

Kidney Disease

Kidney disease was defined as either proteinuria >300 mg/L, albuminuria, or estimated glomerular filtration rate <60 mL-min⁻¹·1.73 m². Albuminuria was defined as either albumin/creatinine ratio ≥30 mg/μg measured in a single morning urine sample, >20 μg/min in timed overnight urine collections, or >30 mg/24 h in a 24-hour urine collection. Glomerular filtration rate was estimated by the Modification of Diet in Renal Disease formula.

Retinopathy

Retinopathy was defined as laser treatment for diabetic retinopathy; Early Treatment Diabetic Retinopathy Study (ETDRS) staging ≥20 shown by fundus photography; Diabetic Retinopathy Disease Severity Scale 3, 4, or 5 shown by dilated ophthalmoscopy, or maculopathy defined as moderate or severe with the Diabetic Macular Edema Disease Severity Scale, determined by dilated ophthalmoscopy with slit lamp or by biomicroscopy.

Measurements

All data were obtained from reviews of medical records. Fasting samples were obtained from 73% of case subjects and 76% of control subjects. Nonfasting samples were obtained in 10% of case subjects and 8% of control subjects. The remainder, 17% of case subjects and 16% of control subjects, lacked the information. Total cholesterol, HDL-C, LDL-C (measured directly or calculated), and triglycerides were assayed within the 6 months before the date of the index visit. Data obtained included age, sex, duration of diabetes mellitus, body weight, height, ethnicity, history of hypertension, blood pressure, current medical treatment, medications, smoking, cardiovascular diseases, fasting blood glucose, and hemoglobin A₁c (HbA₁c).

Quality Control

Quality control visits by the Data Coordinating Center team were conducted at 17 of the 24 sites. CMIC, a contract research organization in Japan, monitored the 3 Japanese sites. On-site single entry of data (with programmatic constraints to prevent out-of-range values

Key Words: diabetes mellitus ■ diabetic retinopathy ■ epidemiology ■ kidney ■ lipids ■ risk factors
and to minimize missing data) was performed with data management software developed for this project. A 5% random sample of medical charts corresponding to digital study data were requested for review by the data coordinating center; 21 of the study sites complied with the request. Values for participant age, sex, race, LDL-C, triglycerides, HDL-C, and outcome status were checked for concordance between the medical records and the study database. The overall discordance rate was 1.2%. Precision and accuracy of laboratories used by participating sites were assessed (online-only Data Supplement).

Sample Size Determination
Prevalence and incidence statistics derived from the PROCAM study (G. Assmann, written communication, April 8, 2008) were used to obtain a target sample size of 100 case subjects in each clinical site, matched 1:1 with control subjects, which would provide 80% power to identify a relative risk of microvascular complications of 2.0 in any site, assuming a 30% prevalence of dyslipidemia among control subjects.37,38 Collection of data on additional control subjects, when available, was allowed as a means of increasing power.

Data Analysis
The primary outcome was a diagnosis of kidney disease, retinopathy, or both, according to the protocol. Kidney disease and retinopathy were analyzed as individual outcomes in secondary analyses that included sites that reported ≥10 cases of either event for each site. Multivariable data on all N1 case subjects and N2 control subjects was assembled into a distance matrix of dimension (N1 + N2) x (N1 + N2). The optimal partitioning of the full data set into strata that included at least 1 case and 1 control per stratum was determined by use of the Hansen and Kloper procedure49 (which in turn uses graph-theoretical optimization procedures attributable to Bertsekas and Tseng); no control was used in >1 stratum. The partitioning is optimal in the sense that no other partition has a smaller sum of within-stratum distances; that is, the groupings together of case and control subjects maximizes the similarities of case subjects to control subjects among all possible groupings. Strata were required to be homogeneous in sex and were formed to minimize the sum of squared Mahalanobis distances over all possible groupings of case and control subjects within sites. Mahalanobis distance was computed based on values of LDL-C, number of years elapsed subsequent to diabetes mellitus diagnosis, and age.

Statistical modeling proceeded along 3 main axes. Case prediction models took several different forms. Most parsimoniously, quintiles of triglycerides and HDL-C were scored 0 to 4, and a single degree of freedom test for trend was used. Separate quintile effects were also estimated to assess adequacy of the linearity assumption. Third, tests of triglycerides and HDL-C effects were conducted marginally (unadjusted); adjusted for statin treatment, hypertension status, and quintile scored HbA1c; and with “mutual” adjustment, in which triglycerides and HDL-C effects were assessed simultaneously. For 1 site, Toronto (2), the hypertension covariate was unavailable, and models for that site excluded this variable.

Statistics were summarized across sites by use of a random effects meta-analysis methodology.40 Finally, several sensitivity analyses were performed on subsamples of the case subjects and on cases with the 4 specific retinopathy definitions. Results are presented as odds ratio (95% confidence limits). For some subgroups, full covariate adjustment was infeasible owing to data sparseness, and adjustments were limited to feasible variables.

Results
Characteristics of Case and Control Subjects
A total of 2535 case subjects were reported and were matched, within sites and within strata defined by sex, to 3683 control subjects. A total of 2034 strata were formed by the optimal matching procedure. The most common structure for strata was a 1:1 match (1125 such strata were formed), and 92% of strata consisted of 1 or 2 case subjects matched to a group of ≤6 control subjects. Within sites, the median within-stratum age range was computed as a measure of departure from perfect matching on age; its median over all sites was 4.25 years. For duration of diabetes mellitus, the median within-site departure over all sites was 3 years, and for LDL-C level, the median within-site departure over all sites was 0.23 mmol/L. Characteristics of case and control subjects are shown in the Table. The meta-analytic estimates of differences between case and control subjects (denoted Δ) in these characteristics in the matched analyses that were used in the meta-analysis to compute odds ratios (ORs) were very small and not clinically meaningful; for instance, difference in duration of diabetes mellitus was 0.9 years. Information was not available on menopausal status of the women; however, the mean age of the case subjects who were women was 66 years, and 89% were ≥50 years of age.

Kidney disease was present in 1891 case subjects and retinopathy in 1218 case subjects. A total of 574 case subjects had both kidney and eye disease. For the secondary analysis of kidney disease or retinopathy, separately, sites were included that reported ≥10 case subjects. The kidney disease analysis included all 24 sites and 1891 case subjects, whereas the retinopathy analysis included 21 sites and 1202 case subjects. Characteristics of the case and control subjects are shown in the Table, and in each of the sites in Table I in the online-only Data Supplement. Characteristics of the case subjects with diabetic kidney disease and retinopathy were similar.

The primary analysis considered microvascular complication case status, which consisted of a diagnosis of at least 1 of diabetic kidney disease, retinopathy, or maculopathy. Using linear scoring of triglyceride quintiles, the OR for a microvascular complication corresponding to a difference of 1 quintile (=0.5 mmol/L) was 1.16 (95% confidence interval [CI], 1.11–1.22), including the covariates stated in Methods (Figure 1). Using categorical factors for triglyceride quintile membership, the OR comparing fifth to first quintiles was 1.76 (95% CI, 1.38–2.25). For linear scoring of HDL-C quintiles, the OR for a 1-quintile difference (=0.2 mmol/L) was 0.92 (95% CI, 0.88–0.96; Figure 1). The OR comparing fifth to first quintiles of HDL-C was 0.73 (95% CI, 0.60–0.90). When the linear quintile scoring model was fit that included triglyceride and HDL-C simultaneously, the OR for a 1-quintile difference of triglyceride was estimated at 1.15 (95% CI, 1.09–1.22) and that for a 1-quintile difference in HDL-C was estimated at 0.96 (95% CI, 0.91–1.01). Site-to-site variability in triglyceride effects was not statistically significant (P=0.22), with 22 of 24 sites yielding OR estimates >1 in the marginal, linear scoring model. Site-to-site variability in the HDL-C effect was also not statistically significant (P=0.42), and 20 of 24 sites yielded OR estimates <1 for this association. Tests for heterogeneity were generally not significant for any of the analyses (see Figure legends).

A planned secondary analysis was the evaluation of the associations of triglycerides and HDL-C with each of the 2 microvascular event types. The OR for a kidney disease complication corresponding to a difference of 1 quintile in triglycerides (=0.5 mmol/L) was 1.23 (95% CI, 1.16–1.31; Figure 2); the OR estimates were >1.0 in 23 of the 24 sites. Using categorical factors, the OR comparing fifth to first quintiles (2.8
The analysis of retinopathy included 21 sites that submitted ≥10 retinopathy case subjects, and the total number of case subjects was 1202. The OR for a retinopathy complication corresponding to a 1-quintile difference in HDL-C was 0.86 (95% CI, 0.82–0.91; Figure 2); the OR was <1.0 in 23 of the 24 sites. Using categorical factors for HDL-C, the OR comparing fifth to first quintiles was 0.58 (95% CI, 0.47–0.73; Figure 3). In models that mutually adjusted for triglycerides and HDL-C, the OR for kidney disease was 1.20 (95% CI, 1.13–1.28) for a quintile increase in triglycerides and 0.92 (95% CI, 0.87–0.97) for a quintile increase in HDL-C (Figure 4). Kidney disease case subjects could qualify on the basis of albuminuria or low glomerular filtration rate; their characteristics are shown in Tables II and III in the online-only Data Supplement, respectively. The kidney disease ORs for triglycerides and HDL-C, individually and in mutual adjustment, were significant for low glomerular filtration rate (n=522 case subjects) and for albuminuria (n=1517 case subjects; Figure 5; Figures I to VI in the online-only Data Supplement).

The analysis of retinopathy included 21 sites that submitted ≥10 retinopathy case subjects, and the total number of case subjects was 1202. The OR for a retinopathy complication was 1.09 (95% CI, 1.02–1.16) per quintile of triglycerides and 0.93 (95% CI, 0.86–1.0) per quintile of HDL-C using models that controlled for the matching factors only. However, additional control for hypertension and HbA1c weakened these associations, and they did not remain significant. For triglycerides, the OR was 1.04 (95% CI, 0.98–1.11), and for HDL-C it was 0.97 (95% CI, 0.90–1.05; Figure 6). The ratio of triglycerides to HDL-C also did not have a significant association with retinopathy (OR, 1.04 [95% CI, 0.98–1.11] per quintile).

The ORs (95% CIs) for retinopathy per quintile of plasma triglycerides or HDL-C, not mutually adjusted, were determined according to the 4 definitions or conditions: (1) Maculopathy (n=169 case subjects): triglycerides 1.09 (0.95–1.26); high-density lipoprotein (HDL-C) 0.97 (0.78–1.19); (2) laser surgery: triglycerides 1.03 (0.93–1.14), HDL-C 0.93 (0.82–1.06); (3) fundus photography EDTRS: triglycerides 1.04 (0.92–1.16), HDL-C 0.98 (0.82–1.17); and (4) dilated ophthalmoscopy Diabetic Retinopathy Disease Severity score: triglycerides 1.00 (0.92–1.08), HDL-C 1.01 (0.94–1.10). Therefore, the results were similar and not significant across these retinopathy outcomes.

We evaluated the possible influence of coexisting kidney disease status on ORs associated with retinopathy for triglycerides and HDL-C. There were 630 retinopathy case subjects who did not have kidney disease, which constituted 52% of the total retinopathy case subjects. The OR (95% CI) for retinopathy for triglyceride was 0.97 (0.89–1.04) for the subset compared with 1.04 (0.98–1.11) for the total group; for HDL-C...
levels, it was 1.03 (0.93–1.14) for the subset compared with 0.97 (0.90–1.05) for the total group.

Because HbA1c level was strongly associated with case status, the ORs for microvascular diseases, kidney or eye, were determined for those with HbA1c above or below the median, 7.4%. ORs for those with HbA1c above the median (mean HbA1c 9.0% for 1554 case subjects, 8.9% for 1659 control subjects) were 1.14 (1.07–1.22) for triglycerides and 0.96 (0.91–1.03) for HDL; for those below the median (mean HbA1c 6.6% for 901 case subjects and 2007 control subjects), they were 1.15 (1.07–1.24) for triglycerides and 0.87 (0.81–0.93) for HDL. These models were not adjusted for HbA1c. Heterogeneity tests for these analyses were not significant.

There were 564 case subjects who had both kidney disease and retinopathy. The OR for case status of both kidney disease and retinopathy compared with 3318 control subjects was 1.16 (95% CI, 1.07–1.25) for a 1-SD increase in triglyceride and 0.88 (95% CI, 0.80–0.96) for a 1-SD increase in HDL-C, similar to those in the full group.

Adjustment for prevalent cardiovascular disease in the matched conditional logistic regression meta-analysis had little impact on key inferences. The OR (95% CI) for increasing adjacent quintiles of triglyceride was 1.23 (1.15–1.31), and for HDL-C, it was 0.87 (0.82–0.92).

Additional sensitivity analyses evaluating those whose blood sample was taken in the fasting state (n=1306 case subjects) are shown in Supplemental Table III and Supplemental Figure IV. In these analyses, the OR for case status for a 1-SD increase in triglyceride was 1.21 (1.14–1.28) for fasting triglycerides and 0.88 (0.81–0.95) for HDL-C. The OR for case status for a 1-SD increase in fasting triglyceride was 1.22 (1.15–1.29) and for HDL-C, it was 0.87 (0.81–0.93).

Figure 1. Odds ratio (OR) for diabetic kidney disease or retinopathy associated with a quintile increase in blood triglycerides (TG; 0.5 mmol/L) or high-density lipoprotein cholesterol (HDL-C; 0.2 mmol/L). Controlled by matching for age, sex, duration of diabetes mellitus, and low-density lipoprotein cholesterol level and by inclusion of hypertension and hemoglobin A1c in the multiple variable model. Size of symbols is proportional to number of case subjects. Test for heterogeneity among sites: TG, P=0.22; HDL-C, P=0.42. CI indicates confidence interval; and REALIST, Residual Risk Lipids and Standard Therapies study.

Figure 2. Odds ratios (OR) for kidney disease for triglycerides (TG; left) and high-density lipoprotein cholesterol (HDL-C; right), not mutually adjusted. Matching variables, covariates, and symbols are described in the legend to Figure 1. The analysis included all 24 sites and 1891 case subjects. Test for heterogeneity among sites: TG, P=0.14; HDL-C, P=0.58. CI indicates confidence interval; and REALIST, Residual Risk Lipids and Standard Therapies study.
subjects for kidney, 803 for eye) showed an OR (95% CI) for a microvascular complication associated with triglycerides of 1.16 (1.09–1.24) compared with 1.16 (1.11–1.22) for the total group. For a microvascular complication associated with HDL-C, the OR was 0.91 (0.86–0.96) compared with 0.92 (0.88–0.96) for the total group.

Similarly, subgroup analysis of those who were not taking statins or fibrates returned ORs that were the same (or approximately the same) as for the full sample. For kidney disease in the no lipid-treatment group, the OR for a 1-SD change in triglycerides was 1.24 (1.14–1.34), and for HDL-C, it was 0.83 (0.77–0.90; n=704 case subjects and 1570 control subjects). For retinopathy in the no lipid-treatment group, the OR for triglycerides was 0.99 (0.90–1.10), and for HDL-C, it was 0.99 (0.87–1.12; n=549 case subjects and 1318 control subjects).

The associations of triglycerides and HDL-C with kidney disease or retinopathy were similar among the geographic regions and ethnicities. Eight European sites were preponderantly (74%) white, and 9 Asian sites were preponderantly

Figure 3. Quintile-specific odds ratios for diabetic kidney disease associated with levels of blood triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C). Matching variables and covariates are described in the legend to Figure 1. Left, TG and HDL-C not mutually adjusted; right, mutually adjusted. The medians for the quintiles (Q1–Q5) are on the horizontal axis.

Figure 4. Odds ratio (OR) for kidney disease for triglycerides and high-density lipoprotein cholesterol (HDL-C), mutually adjusted. Matching variables, covariates, and symbols are described in the legends to Figures 1 and 2. Test for heterogeneity among sites: TG, P=0.19; HDL-C, P=0.64. CI indicates confidence interval; and REALIST, Residual Risk Lipids and Standard Therapies study.
Plasma Lipids in Diabetic Microvascular Disease

The ORs for adjacent quintiles of triglyceride were 1.13 (95% CI, 1.03–1.23) for Europe and 1.21 (95% CI, 1.10–1.34) for Asia; for adjacent quintiles of HDL-C, the ORs were 0.89 (95% CI, 0.78–1.01) for Europe and 0.94 (95% CI, 0.86–1.02) for Asia.

Discussion

Diabetes mellitus is the major cause of renal failure and vision loss in adults.1–4 Current treatments are effective in reducing the risk of development and progression; however, the residual risk for these complications remains high.6,41,42 Because the prevalence of type 2 diabetes mellitus continues to increase worldwide, it is expected that its major complications, kidney disease and retinopathy, will increase in parallel. New targets and treatments are urgently needed.

In the present study, triglycerides and HDL-C were significantly and independently associated with diabetic microvascular disease and specifically with kidney disease. The associations with retinopathy were not robust after adjustment for hypertension and HbA1c. These associations were similar in magnitude among the sites and among geographic regions.

The strengths of the present study include its global scope of inclusion of sites and consistency of findings, demonstrated by lack of heterogeneity in nearly all of the meta-analyses, which supports wide generalizability across regions and ethnicities.
diabetes mellitus, and LDL-C concentration reduced the probability of confounding and reverse causation. The findings for total microvascular events and for kidney disease were robust after adjustment for hypertension and HbA1c, 2 major influences on the occurrence of diabetic microvascular disease. The present study had a large number of case subjects with diabetic microvascular disease; this reduced the chance of a false-negative, which might have occurred in previous studies on HDL-C and microvascular disease.

Limitations of the present study are its cross-sectional design and the potential for reverse causation; however, a typical example of reverse causation, more aggressive treatment of lipid levels in case subjects, would bias the results to the null, because treatment would decrease triglycerides and raise HDL-C in the case subjects, the opposite of the actual results. It appears likely that matching case and control subjects on LDL-C equalized lipid treatment. The finding that lipid treatments were similar in the 2 groups supports this interpretation. The lipid laboratories at each site were not standardized or calibrated, although the laboratory survey that we conducted did not find serious differences in accuracy among the sites that participated, and the precision measurements were excellent. In any case, it would be unlikely that measurement error could occur differentially between case and control subjects. Although the blood samples were not required to be fasting, most were fasting, the same in case and control subjects, and the results for a fasting subgroup were similar to those for the total group.

Most previous studies reported that high plasma triglycerides were associated with diabetic kidney disease, although several did not find an association. With regard to HDL-C, the published literature is less consistent, with some studies showing a significant association, and others no. Certainly, type 2 errors could account for negative studies. In combination with previous studies, we consider the findings of the present study regarding both high triglycerides and low HDL-C, considered alone or together in multiple variable models with consistent direction of ORs among nearly all the sites and mostly nonsignificant tests of heterogeneity, as compelling evidence that triglycerides and HDL-C are indeed strongly associated with diabetic kidney disease.

The associations for retinopathy of triglycerides and HDL-C were weaker than for kidney disease and less robust after adjustment for known risk factors. The retinopathy literature is mixed with regard to triglycerides, with some studies showing a significant association and others no. For HDL-C, none of the studies found a significant association with diabetic retinopathy, with 1 exception. The large number of case subjects (1202) in the present study provided sensitivity to identify even a relatively weak association between retinopathy and triglycerides and HDL-C if one existed. Measurement error for retinopathy determined by ophthalmoscope or even fundus photography that requires grading has the potential to reduce the strength of associations with triglycerides and HDL-C. However, the results for the association between triglycerides and HDL-C and retinopathy were similar regardless of the specific diagnostic criterion, including laser surgery. The results suggest that associations of triglycerides and HDL-C with retinopathy may be dependent on confounding by other risk factors for microvascular disease, specifically hypertension and HbA1c, as we found.

The integrity of the blood-retinal barrier protects the retina against potentially harmful effects of extravasation of plasma lipoproteins. Apolipoprotein B lipoproteins may damage retinal capillaries, leading to extravasation, and they are present in retinas of diabetic people in proportion to the severity of retinopathy. These mechanistic findings and the present results support the concept that mechanisms involved in regulation or dysregulation of intraretinal lipid transport might be potentially more important than plasma lipid levels in the pathogenesis of diabetic retinopathy. This may differ from the effects of lipoproteins on kidney disease, in which extravasation of lipoproteins may more readily occur than in the retina.

Finally, the present study is restricted to information in clinic and hospital records that contain only standard lipid measurements needed for clinical management. It is possible that specific lipoprotein subfractions could be involved in retinopathy, such as apolipoprotein C-III–containing low-density lipoproteins and HDL that are strongly associated with coronary events and adversely affect endothelial cells or oxidized lipoproteins.

In conclusion, this global study of lipid risk factors for diabetic microvascular disease provides strong evidence for independent associations for high triglycerides and low HDL-C. These associations apply to kidney disease. It is possible that retinopathy may also be affected by triglyceride or HDL-C levels, but the association appears weak. Nevertheless, larger populations and meta-analyses could be helpful to further investigate the relationship between retinopathy and dyslipidemia. Current guidelines for lipid treatment give more emphasis than before to the use of triglycerides and HDL-C for treatment thresholds and targets for macrovascular disease. In view of the large and growing health burden of renal failure in diabetes mellitus, these findings have considerable importance in support of the establishment of additional lipid targets other than LDL-C to benefit the diabetic population at high residual risk for microvascular disease despite current standards of care.

Acknowledgments

We acknowledge the contributions of Najlaa A. Ahmad, Roderick Hamsirani, Tariq Alshaikh, Faryal Mehmood, Moniza Amer, and Wael AlMistehi, King Saud University, Riyadh, Saudi Arabia; Angelo Avogaro, University of Padova, Padova, Italy; Gianluca Bardini, University of Florence, Florence, Italy; Danielle Bedard, Leslie Berndl, and Shelly Perry, St. Michael’s Hospital, Toronto, Ontario, Canada; Michelle England, Fremantle Hospital, Crawley, Australia; Juana A. Flores-Roux, Hospital Del Mar, Barcelona, Spain; Brooke Lamparello, Joslin Diabetes Center, Boston, MA; Lu Ju Ming and Jian Nan, Beijing 301 Military Hospital, Beijing, China; Ivan Pečin and Ognjen Zrinščak, University Hospital Center, Zagreb, Croatia; Karim Takbou, Hospital Jean Verdier, Bondy Cedex, France; Yasmin Sallay and Karri Venn, LMC Endocrinology Centres, Toronto and Oakville, Ontario, Canada; Chiara Tommasi, University of Verona, Verona, Italy; Yi-Ren Huang, Tri-Service General Hospital, Taipei, Taiwan; and Lei Zhang, Jiaotong University, Shanghai, China.
are grateful to all study personnel at each participating site for their dedication to this study.

Sources of Funding
This study was funded by an R3i (Residual Risk Reduction Institute) Foundation grant to Brigham and Women’s Hospital and Harvard School of Public Health and to the individual study sites. The sponsor provided logistical support to the sites and the coordinating center.

Disclosures
Dr Sacks was a board member of the Residual Risk Reduction Institute (R3i), the sponsor of this research, until April 12, 2012. In 2011, he was also paid by R3i for his research/product development services. This interest was reviewed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their institutional policies. He has given expert testimony in patent litigation on the side of Abbott. Dr Hermans is a board member of R3i and was also paid by R3i for his research/product development services. Dr Wanner has received honoraria from Merck and Astellas. Dr Valensi has received honoraria from Abbott. Dr Bunnag has received honoraria from Abbott. Dr Goldenberg has received speakers fees, consultant fees, and research fees from Abbott Laboratories, Merck, AstraZeneca, and Pfizer. Dr Leiter has received research funding from, has provided continuing medical education on behalf of, and/or has acted as a consultant to Abbott, AstraZeneca, Boeringer, BMS, Eli Lilly, GSK, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Servier. Dr Simo has participated on advisory panels for Novartis, Novo Nordisk, Lilly, and Abbott and has received travel, honorarium, and research support from these companies. Dr Reiner has received honoraria from Abbott, Sanofi-Aventis, AstraZeneca, and MSD. Dr Carey provided and was compensated for consulting services to the R3I Foundation. The remaining authors report no conflicts.

References


Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries


Circulation. 2014;129:999-1008; originally published online December 18, 2013;
doi: 10.1161/CIRCULATIONAHA.113.002529
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/129/9/999

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2013/12/18/CIRCULATIONAHA.113.002529.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL
Evaluation of precision and accuracy of measurements of serum lipids

A set of serum standards with blood lipids values that were calibrated to the Centers for Disease Control Lipid Standardization Program, Atlanta, USA, were sent to each laboratory of the participating sites and the blood lipids measured. The standards were taken from four large-volume plasma pools created from plasma collected from 23 healthy volunteers in the laboratory of Dr. Sacks at Harvard School of Public Health. The laboratory study included 11 of the 24 sites. Reasons for not participating were unavailability of import permits for blood plasma (5 sites), lack of a centralized local laboratory (4 sites), and declined (2 sites). In addition, delivery to two sites was delayed for 1 to 2 months, and these sites were excluded. The sites that were included were in Croatia (1), Japan (3), Italy (2), USA (1), Thailand (2), Taiwan (2).

The sites analyzed the standards for triglycerides, total cholesterol, and HDL-cholesterol. The 4 pools, each including a single replicate, were run each day for 3 nonconsecutive days. Linear mixed effects models were used with random effects for site and replicate nested within site. For triglycerides and HDL-C, respectively, the intraclass correlation for replicates was estimated at 0.956 and 0.945; and median correlation with reference values measured at Harvard School of Public Health was 0.998 and 0.991.
Supplemental Table 1. Characteristics of cases and controls in each center

<table>
<thead>
<tr>
<th>Center</th>
<th>Stg1 +HTN</th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>TG</th>
<th>Statin use</th>
<th>Cases</th>
<th>Controls</th>
<th>#Male (%)</th>
<th>(%, N)</th>
<th>yrs. w/DM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia Bangkok</td>
<td>68 (86)</td>
<td>90.3 (24.1)</td>
<td>51.9 (12)</td>
<td>127.3 (56.7)</td>
<td>81 (81)</td>
<td>76 (76)</td>
<td>87.5 (22)</td>
<td>56.9 (15.1)</td>
<td>108.9 (46.9)</td>
<td>83 (83)</td>
</tr>
<tr>
<td>Asia Bangkok (2)</td>
<td>94 (66)</td>
<td>95.4 (19.6)</td>
<td>47.6 (10.9)</td>
<td>139.3 (67.1)</td>
<td>84 (59)</td>
<td>79 (79)</td>
<td>93.6 (20.5)</td>
<td>51.2 (12)</td>
<td>110.9 (55.8)</td>
<td>93 (93)</td>
</tr>
<tr>
<td>Asia Beijing</td>
<td>83 (103)</td>
<td>92 (22.6)</td>
<td>41.4 (16.2)</td>
<td>184.9 (170.8)</td>
<td>7 (9)</td>
<td>54 (70)</td>
<td>96.4 (21.9)</td>
<td>39.5 (9.8)</td>
<td>182.6 (129.7)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Asia Shanghai</td>
<td>64 (64)</td>
<td>102.3 (21.4)</td>
<td>44.1 (12)</td>
<td>179.8 (148.2)</td>
<td>1 (1)</td>
<td>58 (117)</td>
<td>103.6 (20.5)</td>
<td>44.8 (13.4)</td>
<td>188.4 (262.3)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Asia Taipei</td>
<td>80 (80)</td>
<td>86 (21.8)</td>
<td>50 (15.8)</td>
<td>146.8 (115.5)</td>
<td>52 (52)</td>
<td>64 (68)</td>
<td>93.8 (18.5)</td>
<td>50.1 (13.4)</td>
<td>123.5 (78.5)</td>
<td>40 (42)</td>
</tr>
<tr>
<td>Asia Taipei (2)</td>
<td>78 (39)</td>
<td>94.3 (20.5)</td>
<td>40.8 (14.6)</td>
<td>140.2 (60.1)</td>
<td>32 (16)</td>
<td>60 (32)</td>
<td>98.3 (18.4)</td>
<td>38.4 (16.9)</td>
<td>116.9 (51.9)</td>
<td>36 (19)</td>
</tr>
<tr>
<td>Asia Tokyo</td>
<td>90 (54)</td>
<td>99.2 (18.8)</td>
<td>56.7 (18.6)</td>
<td>150.6 (109.3)</td>
<td>50 (30)</td>
<td>57 (69)</td>
<td>100.8 (18.8)</td>
<td>56.8 (16.3)</td>
<td>122.6 (74.8)</td>
<td>48 (57)</td>
</tr>
<tr>
<td>Asia Tokyo (2)</td>
<td>76 (44)</td>
<td>102.2 (21.8)</td>
<td>57.5 (18.7)</td>
<td>146.2 (91.5)</td>
<td>48 (28)</td>
<td>60 (55)</td>
<td>97.3 (21.3)</td>
<td>61.3 (19.8)</td>
<td>129.2 (96.6)</td>
<td>51 (46)</td>
</tr>
<tr>
<td>Asia Tokyo (3)</td>
<td>83 (43)</td>
<td>101.3 (22.5)</td>
<td>50.1 (16.2)</td>
<td>129.7 (76.6)</td>
<td>48 (25)</td>
<td>57 (29)</td>
<td>93.9 (21.7)</td>
<td>50.5 (17.7)</td>
<td>137.4 (201)</td>
<td>29 (15)</td>
</tr>
<tr>
<td>Australia Fremantle</td>
<td>85 (72)</td>
<td>74.4 (25.4)</td>
<td>45.2 (13.6)</td>
<td>180.3 (154.9)</td>
<td>76 (65)</td>
<td>81 (64)</td>
<td>81.6 (26.3)</td>
<td>49.4 (16.1)</td>
<td>134.2 (70.1)</td>
<td>63 (50)</td>
</tr>
<tr>
<td>Europe Barcelona</td>
<td>82 (81)</td>
<td>101.8 (18.9)</td>
<td>39.8 (12.4)</td>
<td>186.5 (84)</td>
<td>69 (68)</td>
<td>64 (129)</td>
<td>104.6 (17.9)</td>
<td>43.1 (14.4)</td>
<td>176.2 (69.6)</td>
<td>45 (90)</td>
</tr>
<tr>
<td>Europe Barcelona (2)</td>
<td>89 (90)</td>
<td>98.3 (18.8)</td>
<td>56.7 (18.6)</td>
<td>150.6 (109.3)</td>
<td>50 (30)</td>
<td>57 (69)</td>
<td>100.8 (18.8)</td>
<td>56.8 (16.3)</td>
<td>122.6 (74.8)</td>
<td>48 (57)</td>
</tr>
<tr>
<td>Europe Bondy</td>
<td>74 (145)</td>
<td>87.2 (25.7)</td>
<td>47.9 (20.9)</td>
<td>148.6 (87.3)</td>
<td>49 (97)</td>
<td>60 (344)</td>
<td>93.5 (23.8)</td>
<td>49.9 (29.6)</td>
<td>133.5 (72.3)</td>
<td>37 (145)</td>
</tr>
<tr>
<td>Europe Brussels</td>
<td>88 (170)</td>
<td>92 (23.1)</td>
<td>43.7 (13.4)</td>
<td>160.3 (88.7)</td>
<td>44 (84)</td>
<td>74 (138)</td>
<td>89.2 (23.2)</td>
<td>46.8 (13.3)</td>
<td>142.3 (41.1)</td>
<td>61 (114)</td>
</tr>
<tr>
<td>Europe Florence</td>
<td>83 (64)</td>
<td>94.2 (24.1)</td>
<td>41.1 (11.1)</td>
<td>160.7 (73.2)</td>
<td>51 (39)</td>
<td>36 (4)</td>
<td>104.1 (16.5)</td>
<td>50.1 (10.9)</td>
<td>112.9 (53.5)</td>
<td>36 (4)</td>
</tr>
<tr>
<td>Europe Padova</td>
<td>89 (90)</td>
<td>97.8 (22)</td>
<td>52.6 (15.4)</td>
<td>145.8 (126.2)</td>
<td>26 (26)</td>
<td>80 (163)</td>
<td>94.9 (22.4)</td>
<td>53.7 (17)</td>
<td>122.7 (66.8)</td>
<td>49 (99)</td>
</tr>
<tr>
<td>Europe Verona</td>
<td>86 (173)</td>
<td>86.6 (21)</td>
<td>48.3 (14.4)</td>
<td>121.9 (58.1)</td>
<td>73 (73)</td>
<td>86 (173)</td>
<td>86.6 (21)</td>
<td>51.4 (12.5)</td>
<td>112.9 (53.4)</td>
<td>71 (143)</td>
</tr>
<tr>
<td>Europe Zagreb</td>
<td>78 (87)</td>
<td>106.1 (24.1)</td>
<td>48.3 (14.1)</td>
<td>175.2 (100.1)</td>
<td>22 (24)</td>
<td>63 (136)</td>
<td>95.3 (30.9)</td>
<td>48.6 (15.8)</td>
<td>184.6 (132.5)</td>
<td>36 (78)</td>
</tr>
<tr>
<td>Middle Riyadh</td>
<td>81 (187)</td>
<td>87.8 (21)</td>
<td>42.5 (10.4)</td>
<td>159.5 (77.6)</td>
<td>35 (80)</td>
<td>58 (135)</td>
<td>88.7 (22.3)</td>
<td>44.1 (10.8)</td>
<td>144.4 (75.6)</td>
<td>26 (59)</td>
</tr>
<tr>
<td>North America Boston</td>
<td>97 (152)</td>
<td>75.8 (19.1)</td>
<td>48.9 (17)</td>
<td>184.7 (111.8)</td>
<td>74 (115)</td>
<td>72 (143)</td>
<td>77.3 (20.4)</td>
<td>52.5 (14.6)</td>
<td>156.6 (102.1)</td>
<td>70 (140)</td>
</tr>
<tr>
<td>North America Toronto</td>
<td>82 (84)</td>
<td>79.8 (25.9)</td>
<td>44.9 (14.5)</td>
<td>138.3 (62.9)</td>
<td>79 (81)</td>
<td>65 (132)</td>
<td>78.8 (22.4)</td>
<td>47.4 (13.9)</td>
<td>125.1 (73.1)</td>
<td>75 (152)</td>
</tr>
<tr>
<td>North America Toronto (2)</td>
<td>33 (21)</td>
<td>72 (22.8)</td>
<td>44 (18.2)</td>
<td>135.4 (72.7)</td>
<td>60 (38)</td>
<td>7 (4)</td>
<td>76.2 (19.9)</td>
<td>49.8 (27.5)</td>
<td>151.9 (124.1)</td>
<td>59 (36)</td>
</tr>
<tr>
<td>North America Toronto (3)</td>
<td>80 (80)</td>
<td>76.8 (21.9)</td>
<td>47.3 (41.6)</td>
<td>143 (79.3)</td>
<td>76 (76)</td>
<td>59 (118)</td>
<td>76.6 (22.1)</td>
<td>45.1 (13.4)</td>
<td>138.5 (72)</td>
<td>86 (172)</td>
</tr>
<tr>
<td>North America Vaughan</td>
<td>80 (83)</td>
<td>75.2 (26.2)</td>
<td>44.5 (13.7)</td>
<td>145.1 (78.4)</td>
<td>76 (79)</td>
<td>70 (141)</td>
<td>80.4 (23.6)</td>
<td>46.6 (14.1)</td>
<td>128.3 (73.8)</td>
<td>76 (151)</td>
</tr>
</tbody>
</table>
SUPPLEMENTAL TABLE 2

Characteristics of cases of microalbuminuria and controls

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>4985</td>
<td>1517</td>
<td>3468</td>
</tr>
<tr>
<td>Male [N, (%)]</td>
<td>2858 (57.3%)</td>
<td>929 (61.2%)</td>
<td>1929 (55.6%)</td>
</tr>
<tr>
<td>White/European</td>
<td>47.1%</td>
<td>45.7%</td>
<td>47.7%</td>
</tr>
<tr>
<td>yrs. w/DM [mean, SD]</td>
<td>11.18 (8.52)</td>
<td>13.86 (9.28)</td>
<td>10.01 (7.89)</td>
</tr>
<tr>
<td>Tot. CHOL [mean, SD]</td>
<td>164.78 (31.18)</td>
<td>164.28 (31.71)</td>
<td>165.01 (30.95)</td>
</tr>
<tr>
<td>LDL-C [mean, SD]</td>
<td>2.32 (0.62)</td>
<td>2.27 (0.64)</td>
<td>2.34 (0.61)</td>
</tr>
<tr>
<td>HDL-C [mean, SD]</td>
<td>1.24 (0.44)</td>
<td>1.19 (0.41)</td>
<td>1.26 (0.45)</td>
</tr>
<tr>
<td>TG [mean, SD]</td>
<td>1.65 (1.16)</td>
<td>1.82 (1.11)</td>
<td>1.58 (1.18)</td>
</tr>
<tr>
<td>Fibrate use (%; N)</td>
<td>7.44 (371)</td>
<td>7.71 (117)</td>
<td>7.32 (254)</td>
</tr>
<tr>
<td>Statin use (%; N)</td>
<td>53.56 (2670)</td>
<td>57.22 (868)</td>
<td>51.96 (1802)</td>
</tr>
<tr>
<td>antiDM use (%; N)</td>
<td>91.9 (4581)</td>
<td>94.53 (1434)</td>
<td>90.74 (3147)</td>
</tr>
<tr>
<td>Nephrpathy (%; N)</td>
<td>30.27 (1509)</td>
<td>99.47 (1509)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Retinopathy (%; N)</td>
<td>9.15 (456)</td>
<td>30.06 (456)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Stg1+HTN (%; N)</td>
<td>71.37 (3558)</td>
<td>83.52 (1267)</td>
<td>66.06 (2291)</td>
</tr>
<tr>
<td>HbA1c [mean, SD]</td>
<td>7.74 (1.66)</td>
<td>8.05 (1.72)</td>
<td>7.61 (1.61)</td>
</tr>
</tbody>
</table>
Supplemental Table 3. Characteristics of cases of low GFR and controls.

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>3401</td>
<td>522</td>
<td>2879</td>
</tr>
<tr>
<td>Male [N, (%)]</td>
<td>1914 (56.3%)</td>
<td>325 (62.3%)</td>
<td>1589 (55.2%)</td>
</tr>
<tr>
<td>White/European</td>
<td>54.5%</td>
<td>49.4%</td>
<td>55.5%</td>
</tr>
<tr>
<td>Age [mean, SD]</td>
<td>61.99 (10.64)</td>
<td>68.6 (9.98)</td>
<td>60.79 (10.31)</td>
</tr>
<tr>
<td>yrs. w/DM [mean, SD]</td>
<td>9.99 (8.11)</td>
<td>15.42 (9.82)</td>
<td>9.01 (7.34)</td>
</tr>
<tr>
<td>Tot. CHOL [mean, SD]</td>
<td>164.88 (31.97)</td>
<td>160.79 (33.82)</td>
<td>165.62 (31.57)</td>
</tr>
<tr>
<td>LDL-C [mean, SD]</td>
<td>2.3 (0.63)</td>
<td>2.16 (0.62)</td>
<td>2.32 (0.63)</td>
</tr>
<tr>
<td>HDL-C [mean, SD]</td>
<td>1.24 (0.48)</td>
<td>1.17 (0.59)</td>
<td>1.25 (0.46)</td>
</tr>
<tr>
<td>TG [mean, SD]</td>
<td>1.67 (1.02)</td>
<td>1.9 (1.03)</td>
<td>1.63 (1.02)</td>
</tr>
<tr>
<td>Statin use (% N)</td>
<td>9.29 (316)</td>
<td>13.03 (68)</td>
<td>8.61 (248)</td>
</tr>
<tr>
<td>Nephropathy (% N)</td>
<td>54.22 (1844)</td>
<td>63.79 (333)</td>
<td>52.48 (1511)</td>
</tr>
<tr>
<td>antiDM use (% N)</td>
<td>90.33 (3072)</td>
<td>93.1 (486)</td>
<td>89.82 (2586)</td>
</tr>
<tr>
<td>Nephropathy (% N)</td>
<td>15.17 (516)</td>
<td>98.85 (516)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Retinopathy (% N)</td>
<td>4.55 (158)</td>
<td>30.27 (158)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Syst+HTN (% N)</td>
<td>66.69 (2336)</td>
<td>88.85 (469)</td>
<td>64.85 (1867)</td>
</tr>
<tr>
<td>HbA1c [mean, SD]</td>
<td>7.6 (1.51)</td>
<td>7.68 (1.42)</td>
<td>7.59 (1.52)</td>
</tr>
</tbody>
</table>
Supplemental Figure 1A: Odds ratio for albuminuria according to triglycerides, not mutually adjusted for HDL-cholesterol. Size of symbols proportional to number of cases.
Supplemental Figure 1B: Odds ratio for albuminuria according to HDL-cholesterol, not mutually adjusted for triglycerides. Size of symbols proportional to number of cases.
Supplemental Figure 2A: Odds ratio for albuminuria according to triglycerides mutually adjusted for HDL-cholesterol. Size of symbols proportional to number of cases.
Supplemental Figure 2B: Odds ratio for albuminuria according to HDL-cholesterol, mutually adjusted for triglycerides. Size of symbols proportional to number of cases.
Supplemental Figure 3. Odds ratio for albuminuria according to quintiles of triglycerides and HDL-cholesterol, not mutually adjusted.
Supplemental Figure 4A: Odds ratio for low GFR and triglycerides, not mutually adjusted. Size of symbols proportional to number of cases.
Supplemental Figure 4B: Odds ratio for low GFR and HDL-cholesterol, not mutually adjusted. Size of symbols proportional to number of cases.
Supplemental Figure 5A. Odds ratio for low GFR and triglycerides, mutually adjusted for HDL-cholesterol. Size of symbols proportional to number of cases.
Supplemental Figure 5B. Odds ratio for low GFR and HDL-cholesterol, mutually adjusted for triglycerides. Size of symbols proportional to number of cases.
Supplemental Figure 6. Odds ratio for low GFR according to quintiles of triglycerides or HDL-cholesterol, not mutually adjusted.